EP3107546A4 - Therapeutic methods employing noribogaine and related compounds - Google Patents
Therapeutic methods employing noribogaine and related compounds Download PDFInfo
- Publication number
- EP3107546A4 EP3107546A4 EP15751574.3A EP15751574A EP3107546A4 EP 3107546 A4 EP3107546 A4 EP 3107546A4 EP 15751574 A EP15751574 A EP 15751574A EP 3107546 A4 EP3107546 A4 EP 3107546A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- noribogaine
- related compounds
- therapeutic methods
- methods employing
- employing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title 1
- RAUCDOKTMDOIPF-UHFFFAOYSA-N hydroxyibogamine Natural products CCC1CC(C2)CC3C1N2CCC1=C3NC2=CC=C(O)C=C12 RAUCDOKTMDOIPF-UHFFFAOYSA-N 0.000 title 1
- RAUCDOKTMDOIPF-RYRUWHOVSA-N noribogaine Chemical compound N1([C@@H]2[C@H]3C[C@H](C1)C[C@@H]2CC)CCC1=C3NC2=CC=C(O)C=C12 RAUCDOKTMDOIPF-RYRUWHOVSA-N 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Addiction (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (23)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461941387P | 2014-02-18 | 2014-02-18 | |
US201461941390P | 2014-02-18 | 2014-02-18 | |
US201461945746P | 2014-02-27 | 2014-02-27 | |
PCT/US2014/019692 WO2015126434A1 (en) | 2014-02-18 | 2014-02-28 | Methods for acute and long-term treatment of drug addiction |
US14/195,822 US9345711B2 (en) | 2014-02-18 | 2014-03-03 | Methods for acute and long-term treatment of drug addiction |
US201461952727P | 2014-03-13 | 2014-03-13 | |
US201461952733P | 2014-03-13 | 2014-03-13 | |
US201461952738P | 2014-03-13 | 2014-03-13 | |
US201461952744P | 2014-03-13 | 2014-03-13 | |
US201461952741P | 2014-03-13 | 2014-03-13 | |
US201461952731P | 2014-03-13 | 2014-03-13 | |
US201462005841P | 2014-05-30 | 2014-05-30 | |
US201462005858P | 2014-05-30 | 2014-05-30 | |
US201462005855P | 2014-05-30 | 2014-05-30 | |
US201462005847P | 2014-05-30 | 2014-05-30 | |
US201462005851P | 2014-05-30 | 2014-05-30 | |
US14/292,632 US20150231146A1 (en) | 2014-02-18 | 2014-05-30 | Methods for acute and long-term treatment of drug addiction |
US201462007346P | 2014-06-03 | 2014-06-03 | |
US201462024388P | 2014-07-14 | 2014-07-14 | |
US201462033538P | 2014-08-05 | 2014-08-05 | |
US201462035335P | 2014-08-08 | 2014-08-08 | |
US14/485,514 US20150231147A1 (en) | 2014-02-18 | 2014-09-12 | Methods for acute and long-term treatment of drug addiction |
PCT/US2015/016186 WO2015126836A2 (en) | 2014-02-18 | 2015-02-17 | Therapeutic methods employing noribogaine and related compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3107546A2 EP3107546A2 (en) | 2016-12-28 |
EP3107546A4 true EP3107546A4 (en) | 2017-10-25 |
Family
ID=53879225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15751574.3A Pending EP3107546A4 (en) | 2014-02-18 | 2015-02-17 | Therapeutic methods employing noribogaine and related compounds |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP3107546A4 (en) |
JP (1) | JP2017506244A (en) |
KR (1) | KR20160124829A (en) |
CN (1) | CN106413718A (en) |
AU (2) | AU2015219172A1 (en) |
CA (2) | CA2977636C (en) |
EA (1) | EA201691656A2 (en) |
IL (1) | IL247325A0 (en) |
TW (1) | TW201534306A (en) |
WO (1) | WO2015126836A2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2942638A1 (en) | 2013-03-15 | 2014-09-18 | Demerx, Inc. | Method for noribogaine treatment of addiction in patients on methadone |
US9561232B2 (en) | 2014-02-18 | 2017-02-07 | Demerx, Inc. | Low dose noribogaine for treating nicotine addiction and preventing relapse of nicotine use |
US9591978B2 (en) | 2014-03-13 | 2017-03-14 | Demerx, Inc. | Methods and compositions for pre-screening patients for treatment with noribogaine |
US9549935B2 (en) | 2014-07-14 | 2017-01-24 | Demerx, Inc. | Methods and compositions for treating migraines using noribogaine |
ES2867174T3 (en) | 2014-11-26 | 2021-10-20 | Demerx Inc | Methods and compositions to enhance the action of opioid analgesics through the use of iboga alkaloids |
CN113496072B (en) * | 2020-03-22 | 2024-07-02 | 杭州环特生物科技股份有限公司 | Conversion method for converting human dose of zebra fish for safety evaluation |
WO2024145462A1 (en) * | 2022-12-29 | 2024-07-04 | Atai Therapeutics, Inc. | Ibogaine and noribogaine analogs and methods of use |
WO2024145464A2 (en) * | 2022-12-29 | 2024-07-04 | Atai Therapeutics, Inc: | Ibogaine and noribogaine prodrugs and methods of use |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996003127A1 (en) * | 1994-07-25 | 1996-02-08 | Nda International, Inc. | A method of treating chemical dependency in mammals and a composition therefor |
WO1999011250A2 (en) * | 1997-09-04 | 1999-03-11 | Novoneuron, Inc. | Noribogaine in the treatment of pain and drug addiction |
US7220737B1 (en) * | 1997-09-04 | 2007-05-22 | Novoneuron, Inc | Noribogaine in the treatment of pain and drug addiction |
WO2014144508A2 (en) * | 2013-03-15 | 2014-09-18 | Demerx, Inc. | Method for non-toxic treatment for drug withdrawal |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030153552A1 (en) * | 2002-02-14 | 2003-08-14 | Mash Deborah C. | Method of treating chemical dependency in mammals and a composition therefor |
WO2012012764A1 (en) * | 2010-07-23 | 2012-01-26 | Demerx, Inc. | Noribogaine compositions |
-
2015
- 2015-02-17 KR KR1020167025602A patent/KR20160124829A/en unknown
- 2015-02-17 TW TW104105711A patent/TW201534306A/en unknown
- 2015-02-17 AU AU2015219172A patent/AU2015219172A1/en not_active Abandoned
- 2015-02-17 WO PCT/US2015/016186 patent/WO2015126836A2/en active Application Filing
- 2015-02-17 CA CA2977636A patent/CA2977636C/en active Active
- 2015-02-17 CA CA3221251A patent/CA3221251A1/en active Pending
- 2015-02-17 EP EP15751574.3A patent/EP3107546A4/en active Pending
- 2015-02-17 JP JP2016552622A patent/JP2017506244A/en active Pending
- 2015-02-17 EA EA201691656A patent/EA201691656A2/en unknown
- 2015-02-17 CN CN201580020072.5A patent/CN106413718A/en active Pending
-
2016
- 2016-08-17 IL IL247325A patent/IL247325A0/en unknown
-
2020
- 2020-11-11 AU AU2020267217A patent/AU2020267217B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996003127A1 (en) * | 1994-07-25 | 1996-02-08 | Nda International, Inc. | A method of treating chemical dependency in mammals and a composition therefor |
WO1999011250A2 (en) * | 1997-09-04 | 1999-03-11 | Novoneuron, Inc. | Noribogaine in the treatment of pain and drug addiction |
US7220737B1 (en) * | 1997-09-04 | 2007-05-22 | Novoneuron, Inc | Noribogaine in the treatment of pain and drug addiction |
WO2014144508A2 (en) * | 2013-03-15 | 2014-09-18 | Demerx, Inc. | Method for non-toxic treatment for drug withdrawal |
Non-Patent Citations (4)
Title |
---|
HEMENDRA N BHARGAVA ET AL: "Effects of noribogaine on the development of tolerance to antinociceptive action of morphine in mice", BRAIN RESEARCH, vol. 771, no. 2, 1 October 1997 (1997-10-01), AMSTERDAM, NL, pages 343 - 346, XP055406445, ISSN: 0006-8993, DOI: 10.1016/S0006-8993(97)00914-1 * |
KOENIG XAVER ET AL: "Anti-addiction drug ibogaine inhibits voltage-gated ionic currents: A study to assess the drug's cardiac ion channel profile", TOXICOLOGY AND APPLIED PHARMACOLOGY, vol. 273, no. 2, 22 May 2013 (2013-05-22), pages 259 - 268, XP028784922, ISSN: 0041-008X, DOI: 10.1016/J.TAAP.2013.05.012 * |
MICHAEL BAUMANN: "In vivo neurobiological effects of ibogaine and its O-desmethyl methabolite, 12-hydroxyibogamine (noribogaine) in rats)", 1 January 2001 (2001-01-01), XP055405640, Retrieved from the Internet <URL:http://jpet.aspetjournals.org/content/jpet/297/2/531.full.pdf> [retrieved on 20170912] * |
STALLVIK MARIANNE ET AL: "Corrected QT interval during treatment with methadone and buprenorphine-Relation to doses and serum concentrations", DRUG AND ALCOHOL DEPENDENCE, ELSEVIER SCIENTIFIC PUBLISHERS, IR, vol. 129, no. 1, 16 October 2012 (2012-10-16), pages 88 - 93, XP028988598, ISSN: 0376-8716, DOI: 10.1016/J.DRUGALCDEP.2012.09.016 * |
Also Published As
Publication number | Publication date |
---|---|
CN106413718A (en) | 2017-02-15 |
JP2017506244A (en) | 2017-03-02 |
EP3107546A2 (en) | 2016-12-28 |
WO2015126836A2 (en) | 2015-08-27 |
AU2015219172A1 (en) | 2016-09-29 |
KR20160124829A (en) | 2016-10-28 |
EA201691656A2 (en) | 2017-03-31 |
AU2020267217A1 (en) | 2020-12-03 |
CA2977636C (en) | 2024-01-02 |
TW201534306A (en) | 2015-09-16 |
AU2020267217B2 (en) | 2022-04-07 |
CA2977636A1 (en) | 2015-08-27 |
CA3221251A1 (en) | 2015-08-27 |
IL247325A0 (en) | 2016-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3359168A4 (en) | Therapeutic compounds and methods | |
HK1243073A1 (en) | Therapeutic compounds and uses thereof | |
EP3380101A4 (en) | Eif4-a-inhibiting compounds and methods related thereto | |
EP3199628A4 (en) | Cytotoxicity-inducing therapeutic agent | |
EP3154594A4 (en) | Fap-activated therapeutic agents, and uses related thereto | |
EP3218005A4 (en) | Glycan-interacting compounds and methods of use | |
EP3102200A4 (en) | Therapeutic compounds and compositions | |
EP3229809A4 (en) | Compounds and methods involving sterols | |
EP3020430A4 (en) | Cannula for catgut-embedding therapy | |
IL247325A0 (en) | Therapeutic methods employing noribogaine and related compounds | |
EP3097880A4 (en) | Therapeutic apparatus | |
EP3126634A4 (en) | Well stimulation | |
EP3231793A4 (en) | Dihydropyrimidine-2-one compounds and medicinal uses thereof | |
EP3141647A4 (en) | Wadding | |
EP3111932A4 (en) | Ketoprofen-containing poultice | |
EP3193878A4 (en) | Compounds and methods | |
EP3238725A4 (en) | Poultice | |
EP3259254A4 (en) | Therapeutic compounds | |
EP3171876A4 (en) | Combination therapy | |
EP3119199A4 (en) | Compounds and their methods of use | |
EP3204042A4 (en) | Psma-related therapies | |
EP3190116A4 (en) | Pyrazolothiazole compound and medicine | |
EP3160492A4 (en) | Helicobacter therapeutic | |
EP3197470A4 (en) | Cis-gnetin h and trans-gnetin h as therapeutic agents | |
EP3225240A4 (en) | Medicine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20160913 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20170926 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/30 20060101ALI20170920BHEP Ipc: A61K 31/55 20060101AFI20170920BHEP Ipc: A61P 25/04 20060101ALI20170920BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20190408 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |